Chester Porphyria

Back

Practice Essentials

Porphyrias are inborn errors of metabolism in which specific enzyme defects exist in the heme synthesis pathway. Chester porphyria is a unique type of porphyria, with the clinical picture of acute intermittent porphyria (AIP) and the biochemical defects of both acute intermittent porphyria and variegate porphyria (VP).[1]

 

Background

The first description of Chester porphyria is from a clinical observation made in 1963 by an anesthetist, Zorka Bekerus, in Chester, England (hence the name Chester porphyria). The index case, Peter Dobson, was a salmon fisherman born in 1867 in Chester.[2, 3]  Numerous family members had the condition, and the family had coined the term Dobson's complaint to describe the mysterious illness.[4, 5]

Pathophysiology

Chester porphyria does not conform to any of the recognized types of acute porphyria (see image below).



View Image

This schematic diagram of biochemical abnormality shows the sites of enzymatic defects of the various porphyrias on the left side of the diagram and t....

The urine porphyrin excretory pattern varies from the pattern of acute intermittent porphyria to variegate porphyria. Chester porphyria exhibits reduction in enzymatic activity of both porphobilinogen deaminase (an enzyme with reduced activity in acute intermittent porphyria) and protoporphyrinogen oxidase (an enzyme with reduced activity in variegate porphyria). Chester porphyria manifests with attacks of neurovisceral dysfunction common to all acute porphyrias. Unlike in variegate porphyrias, cutaneous photosensitivity is not a feature of Chester porphyria.

Etiology

Genetic studies have linked the Chester porphyria gene to chromosome arm 11q.[6] Precipitating factors of Chester porphyria attacks include the following drugs:

Other precipitating factors are as follows:

Epidemiology

The frequency of Chester porphyria is low, and it is only described in the city of Chester, England.

Prognosis

The mortality rate of Chester porphyria is high. Morbidity is significant. Many members of the Chester family were afflicted with hypertension and renal disease. Significant morbidity is associated with painful porphyric crises in patients affected with Chester porphyria. Tracing of the ancestry of the Chester family shows that 14 members had peripheral motor neuropathy; 6 of the 14 developed bulbar palsy, and 4 died as a result.[2, 3]

Complications of Chester porphyria include the following:

Patient Education

Genetic counseling and discussion about Chester porphyria are essential components of clinical management.

History

Patients with Chester porphyria may present with the following history:

Physical Examination

Patients with Chester porphyria may present with the following physical findings:

Skin manifestations are not seen in Chester porphyria.

Laboratory Studies

Laboratory workup for Chester porphyria includes the following:

Medical Care

Currently, no cure exists for Chester porphyria. The goal of management is to avoid precipitating factors in cases of suspected porphyrias. Treatment is symptomatic. Genetic counseling and understanding the disease and its manifestations may be helpful for family members.

Surgical Care

Patients with Chester porphyria are at risk of an acute attack of porphyria at the time of surgery. This is because of stress, metabolic abnormalities, and certain drugs used during surgery.

Author

Koyamangalath Krishnan, MD, FRCP, FACP, Dishner Endowed Chair of Excellence in Medicine, Professor of Medicine, James H Quillen College of Medicine at East Tennessee State University

Disclosure: Nothing to disclose.

Coauthor(s)

Harsha G Vardhana, MD, Chief Fellow, Medical Oncology, Department of Internal Medicine, James H Quillen College of Medicine at East Tennessee State University

Disclosure: Nothing to disclose.

Stephen J Smith, MD, Assistant Professor of Medicine, Department of Internal Medicine, Division of Hematology/Oncology, East Tennessee State University, James H. Quillen College of Medicine

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Marcel E Conrad, MD, Distinguished Professor of Medicine (Retired), University of South Alabama College of Medicine

Disclosure: Partner received none from No financial interests for none.

Chief Editor

Emmanuel C Besa, MD, Professor Emeritus, Department of Medicine, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Disclosure: Nothing to disclose.

Additional Contributors

Clarence Sarkodee Adoo, MD, FACP, Consulting Staff, Department of Bone Marrow Transplantation, City of Hope Samaritan BMT Program

Disclosure: Nothing to disclose.

References

  1. Poblete-Gutiérrez P, Wiederholt T, Martinez-Mir A, et al. Demystification of Chester porphyria: a nonsense mutation in the porphobilinogen deaminase gene. Physiol Res. 2006. 55 suppl 2:S137-44. [View Abstract]
  2. Crimlisk H. Dobson's complaint: the story of the Chester porphyria. BMJ. 1999 Jan 30. 318(7179):336A. [View Abstract]
  3. Youngs GR, ed. Dobson's Complaint: The Story of the Chester Porphyria. London, England: The Royal College of Physicians of London; 1998.
  4. McColl KE, Thompson GG, Moore MR, et al. Chester porphyria: biochemical studies of a new form of acute porphyria. Lancet. 1985 Oct 12. 2(8459):796-9. [View Abstract]
  5. Qadiri MR, Church SE, McColl KE, Moore MR, Youngs GR. Chester porphyria: a clinical study of a new form of acute porphyria. Br Med J (Clin Res Ed). 1986 Feb 15. 292(6518):455-9. [View Abstract]
  6. Norton B, Lanyon WG, Moore MR, et al. Evidence for involvement of a second genetic locus on chromosome 11q in porphyrin metabolism. Hum Genet. 1993 Jul. 91(6):576-8. [View Abstract]
  7. Bonkowsky HL, Schady W. Neurologic manifestations of acute porphyria. Semin Liver Dis. 1982 May. 2(2):108-24. [View Abstract]
  8. Pischik E, Kazakov V, Kauppinen R. Is screening for urinary porphobilinogen useful among patients with acute polyneuropathy or encephalopathy?. J Neurol. 2008 Jul. 255(7):974-9. [View Abstract]
  9. Billoo AG, Lone SW. A family with acute intermittent porphyria. J Coll Physicians Surg Pak. 2008 May. 18(5):316-8. [View Abstract]
  10. Church SE. The Chester porphyria. MD thesis, University of Liverpool, United Kingdom. 1986.
  11. Sardh E, Rejkjaer L, Andersson DE, Harper P. Safety, pharmacokinetics and pharmacodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. Clin Pharmacokinet. 2007. 46(4):335-49. [View Abstract]

This schematic diagram of biochemical abnormality shows the sites of enzymatic defects of the various porphyrias on the left side of the diagram and the dual enzyme abnormality of Chester porphyria (deficiency of porphobilinogen deaminase [PBGD] and protoporphyrinogen oxidase) on the right. ALA = delta-aminolevulinate; COPRO = copro-porphyrin; HMB = hydroxymethylbilane; HMB-S = hydroxymethylbilane synthase; PROTO = protoporphyrin; URO = uroporphyrin.

This schematic diagram of biochemical abnormality shows the sites of enzymatic defects of the various porphyrias on the left side of the diagram and the dual enzyme abnormality of Chester porphyria (deficiency of porphobilinogen deaminase [PBGD] and protoporphyrinogen oxidase) on the right. ALA = delta-aminolevulinate; COPRO = copro-porphyrin; HMB = hydroxymethylbilane; HMB-S = hydroxymethylbilane synthase; PROTO = protoporphyrin; URO = uroporphyrin.